DE60213232D1 - Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen - Google Patents

Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen

Info

Publication number
DE60213232D1
DE60213232D1 DE60213232T DE60213232T DE60213232D1 DE 60213232 D1 DE60213232 D1 DE 60213232D1 DE 60213232 T DE60213232 T DE 60213232T DE 60213232 T DE60213232 T DE 60213232T DE 60213232 D1 DE60213232 D1 DE 60213232D1
Authority
DE
Germany
Prior art keywords
treatment
medicaments
virus infections
targeted release
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213232T
Other languages
English (en)
Other versions
DE60213232T2 (de
Inventor
Ward Page Faulk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faulk Pharmaceuticals Inc
Original Assignee
Faulk Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulk Pharmaceuticals Inc filed Critical Faulk Pharmaceuticals Inc
Publication of DE60213232D1 publication Critical patent/DE60213232D1/de
Application granted granted Critical
Publication of DE60213232T2 publication Critical patent/DE60213232T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60213232T 2001-05-15 2002-05-15 Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen Expired - Lifetime DE60213232T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29066801P 2001-05-15 2001-05-15
US290668P 2001-05-15
US35539402P 2002-02-08 2002-02-08
US355394P 2002-02-08
PCT/US2002/011892 WO2002092116A1 (en) 2001-05-15 2002-05-15 Targeted delivery of drugs for the treatment of viral infections

Publications (2)

Publication Number Publication Date
DE60213232D1 true DE60213232D1 (de) 2006-08-31
DE60213232T2 DE60213232T2 (de) 2007-07-26

Family

ID=26966345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213232T Expired - Lifetime DE60213232T2 (de) 2001-05-15 2002-05-15 Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen

Country Status (9)

Country Link
US (1) US8183208B2 (de)
EP (1) EP1395273B1 (de)
JP (1) JP2004537515A (de)
CN (1) CN100372566C (de)
AT (1) ATE333288T1 (de)
CA (1) CA2447335C (de)
DE (1) DE60213232T2 (de)
PL (1) PL367244A1 (de)
WO (1) WO2002092116A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395273B1 (de) 2001-05-15 2006-07-19 Faulk Pharmaceuticals, Inc. Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
WO2002094271A1 (en) * 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
PL366637A1 (en) * 2001-05-16 2005-02-07 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
CA2869088A1 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatments
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
EP4005600A1 (de) * 2012-04-26 2022-06-01 Yale University Gegen hiv gerichtete zytotoxische wirkstoffe freisetzende moleküle (cdm-hs), zytotoxische wirkung gegen das menschliche immunschwächevirus und verfahren zur verwendung
CN107304424B (zh) * 2016-05-23 2019-05-10 成都福际生物技术有限公司 改造的转铁蛋白dna结合域、重组dna聚合酶及制备方法
US20180236098A1 (en) * 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979B (en) 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
GB8519457D0 (en) 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
IN165717B (de) 1986-08-07 1989-12-23 Battelle Memorial Institute
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5238940A (en) 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5268165A (en) 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
US5326778A (en) 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US6066319A (en) * 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US5919643A (en) * 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
WO2000033884A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugates of lipids and antimicrobial or antineoplastic drugs
GB9908195D0 (en) * 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
JP2004501171A (ja) 2000-06-28 2004-01-15 フォーク　ワード　ページ Ａ）臓器が移植された患者における活性化されたリンパ球への、ｂ）放射線療法を受ける患者における、癌細胞への放射線増感剤としての、ｃ）癌の診断および治療における薬物担体としてのビタミン結合タンパク質中の、細胞毒の標的指向型送達
US20020137901A1 (en) 2001-01-22 2002-09-26 Cavanaugh Philip Gerard Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
FR2824563B1 (fr) 2001-05-10 2004-12-03 Bio Merieux Particules composites, conjugues derives, procede de preparation et applications
EP1395273B1 (de) 2001-05-15 2006-07-19 Faulk Pharmaceuticals, Inc. Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
WO2002094271A1 (en) * 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
PL373511A1 (en) * 2001-05-15 2005-09-05 Faulk Pharmaceuticals, Inc. Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use
PL366637A1 (en) 2001-05-16 2005-02-07 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
US20040220086A1 (en) 2001-10-17 2004-11-04 Faulk W. Page Methods and materials for targeting and affecting selected cells

Also Published As

Publication number Publication date
EP1395273A4 (de) 2004-08-18
JP2004537515A (ja) 2004-12-16
CA2447335C (en) 2011-01-04
CN100372566C (zh) 2008-03-05
CA2447335A1 (en) 2002-11-21
US20080103094A1 (en) 2008-05-01
EP1395273A1 (de) 2004-03-10
EP1395273B1 (de) 2006-07-19
WO2002092116A1 (en) 2002-11-21
CN1529612A (zh) 2004-09-15
DE60213232T2 (de) 2007-07-26
US8183208B2 (en) 2012-05-22
ATE333288T1 (de) 2006-08-15
PL367244A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
NZ515392A (en) Respiratory syncytial virus replication inhibitors
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
NZ526088A (en) Urea substituted imidazoquinoline ethers
DK0746327T3 (da) Forsuret nitrit som antimikrobielt middel
AU2003227890A1 (en) Immobilisation and stabilisation of virus
PE20001112A1 (es) Derivados de quinolina como agentes antibacterianos
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
PT1142887E (pt) Derivados de 5,6-di-hidropirona como inibidores de protease e agentes antivirais
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE60213232D1 (de) Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ATE433459T1 (de) Desoxo-nonadepsipeptide
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
AU2002327970A1 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
AU2396900A (en) Treatment and prevention of hiv and other viral infections

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN